After the success of the ELIANA (NCT02435849) and JULIET (NCT02445248) trials, which investigated tisagenlecleucel, an anti-CD19 CAR T cell construct, for the treatment of pediatric patients with relapsed/refractory B-ALL and adults with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL), respectively, the anti-CD19 CAR T cells have been approved by the FDA [112,113]. Here, CD19 is linked to acute lymphoblastic leukemia.